The MSO Uplisting Question: Why Nobody Agrees, and What's Actually True

The State of Play in One Paragraph

A US cannabis multi-state operator (MSO) wanting to trade on the NYSE or NASDAQ today faces three barriers stacked on top of each other: (1) a partial April 23, 2026 rescheduling order that moved only FDA-approved cannabis drugs and state-licensed medical marijuana to Schedule III — adult-use remains Schedule I; (2) exchange listing standards that aren't quantitative but discretionary, anchored in NASDAQ Rule 5101's prohibition on listing companies "whose current or planned activities are in violation of U.S. federal law"; and (3) a custody/clearing/banking infrastructure that won't extend full institutional access until federal AML exposure is statutorily cleaned up. None of these falls because of SAFE Banking. None of them falls because of Schedule III alone. The bill that would actually do it — the CLIMB Act (H.R. 7987) — is sitting unread in the House. Meanwhile Trulieve announced a Delaware redomicile on May 13 (three days ago), Verano completed a Nevada redomicile in November 2025, Curaleaf is on the TSX, and the MSOS ETF is held together by total return swaps with five non-US-bank counterparties. Every piece of this is being misread by someone with a megaphone.

Let's untangle it.

---

Part 1 — Where MSOs Actually Trade Today

The headline number: as of mid-May 2026, zero US plant-touching cannabis companies are listed on the NYSE, NASDAQ, NYSE American, or any other US national exchange. They trade in a two-jurisdiction split structure:

Canadian primary listings — required because Canadian exchanges (the CSE and Cboe Canada) historically permitted what US exchanges wouldn't. The TSX joined the party in 2023 but only via an ownership-restructuring workaround.

OTC Markets secondary listings — where US investors actually transact.

The current map

Curaleaf — Canadian primary: TSX (CURA). US OTC: OTCQX (CURLF). Uplisted from the CSE to the TSX on Dec 14, 2023 via a restructured US subsidiary.

Green Thumb Industries — Canadian primary: CSE (GTII). US OTC: OTCQX (GTBIF). On the CSE since its IPO.

Trulieve — Canadian primary: CSE (TRUL). US OTC: OTCQX (TCNNF). Delaware redomicile pending an Aug 5, 2026 shareholder vote.

Verano — Canadian primary: Cboe Canada (VRNO). US OTC: OTCQX (VRNOF). Left the CSE in Oct 2023; redomiciled to Nevada on Nov 3, 2025.

Cresco Labs — Canadian primary: CSE (CL). US OTC: OTCQX (CRLBF). Still on the CSE.

Ascend Wellness — Canadian primary: CSE (AAWH.U). US OTC: OTCQX (AAWH). Already Delaware-incorporated since 2021.

TerrAscend — Canadian primary: TSX (TSND). US OTC: OTCQX (TSNDF). First MSO to crack the TSX, in July 2023.

Glass House Brands — Canadian primary: Cboe Canada (GLAS.A.U). US OTC: OTCQX (GLASF). A SPAC since 2021.

Jushi Holdings — Canadian primary: CSE (JUSH). US OTC: OTCQX (JUSHF). Still on the CSE.

Schwazze — No Canadian listing. US OTC: Expert Market (SHWZ) — the most restrictive OTC tier, broker-dealer-only and blocked by most retail platforms. Downgraded in July 2024 after its auditor (BF Borgers) was sanctioned by the SEC.

Cannabist (formerly Columbia Care) — Canadian primary: Cboe Canada. US OTC: CBSTF. Off the CSE since 2023.

Planet 13 — Canadian primary: CSE (PLTH). US OTC: OTCQX (PLNHF). Still on the CSE.

The three Canadian venues are not interchangeable. The TSX flatly prohibits US plant-touching exposure unless the issuer restructures so the parent doesn't legally "own" the US ops — TerrAscend cracked this in July 2023 by isolating its US business in TerrAscend Growth Corp., and Curaleaf followed in December 2023 by spinning a Curaleaf USA subsidiary with an independent shareholder holding the voting share for $1 million. Cboe Canada (the renamed NEO Exchange after Cboe Global Markets' 2022 acquisition) is more accommodating than TSX without the restructuring requirement. CSE remains the default for everyone else; CEO Richard Carleton built the franchise on hosting what TSX wouldn't.

New Cannabis Ventures has argued bluntly that "the Canadian listing does not matter for American cannabis companies" — most volume flows through the OTC ticker, not the primary. There's a real disagreement here, but the numerical case is strong: even Curaleaf's TSX uplisting, which the bull thesis cast as transformative, has been a fizzle. CURA stock hit C$8.73 in April 2024 on rescheduling rumors, then crashed to C$0.99 by June 2025 as the process stalled. Canadian institutional mandates with US-plant-touching exclusions don't care which Canadian ticker you use.

OTC tiers — what investors actually need to know

OTC Markets Group runs four tiers: OTCQX (best, requires audited financials, $2M+ net tangible assets, $0.25 bid minimum, sponsor letter), OTCQB, OTCID/Pink Current (rebranded effective July 2025), and Pink Limited / Expert Market (broker-dealer-only — retail platforms typically block these).

Most large MSOs sit on OTCQX. Schwazze's July 2024 demotion to the Expert Market is the cautionary tale: when BF Borgers (its auditor) got hit with SEC sanctions, Schwazze couldn't file its 10-Q on time and dropped two tiers. By October 2025 it was in restructuring; Vireo Growth bought $91M of converts for $62M, and subsequent defaults followed. The OTCQX-to-Expert-Market gap is the difference between a tradeable security and an institutional pariah.

What OTCQX does not buy you: DTC eligibility automatically (most majors have it separately), NMS-listed status, index inclusion, or unrestricted access through major brokerages. Schwab and Fidelity will execute retail OTC cannabis trades; Robinhood and many advisor platforms block them outright.

The liquidity reality

Granular ADV data is thin in public sources. What we can confirm:

• MSOS ETF (the de facto sector benchmark): ADV ~6.5M shares, AUM ~$908M to $1.09B depending on which date you anchor.
• MSOS top three concentration: As of May 15, 2026, Curaleaf 31.4% / Trulieve 22.1% / GTI 19.1% = 72.5% of the fund in three names. Add Glass House, Cresco, Verano, TerrAscend, Jushi — top eight = ~97%. This is concentration risk masquerading as diversification.
• MSOS performance: Down 36.8% from the Dec 18, 2025 Trump executive order intraday peak through early May 2026. Down 87.1% over five years (from $36.50 to $4.72).
• OTC native volumes are a small fraction of the synthetic exposure flowing through MSOS swaps.

---

Part 2 — The MSOS Swap Machine: How Wall Street Already Touches the Plant

This is the single most underappreciated piece of plumbing in the sector, so it gets its own section.

The AdvisorShares Pure US Cannabis ETF (MSOS, NYSE Arca, launched Sept 1, 2020) cannot directly hold most of the MSOs in its name. Plant-touching equities don't qualify for the ETF's exchange-listed status. So MSOS gets its exposure through total return swaps (TRS) with broker-dealer counterparties. The counterparties hold (or hedge) the underlying OTC names and pay MSOS the total return; MSOS pays a financing rate (typically SOFR + 50-200 bps).

Current swap counterparties per AdvisorShares disclosures: Nomura (~22% of fund), National Bank of Canada, Marex, CF Secured (a Cantor Fitzgerald subsidiary), and Clear Street. Cantor Fitzgerald itself exited as a direct counterparty in March 2022.

What this list tells you that nobody says out loud: not one bulge-bracket US bank — no Goldman, no Morgan Stanley, no JPMorgan, no BofA — is on this list. Five years into the sector's mainstream ETF existence, the swap book is held by one Japanese bank, one Canadian bank, one UK commodities specialist, one Cantor subsidiary, and one independent prime broker. That's the actual measure of institutional comfort, and it hasn't materially changed.

Two other tells:

• MSOX accounting restatement (Feb 2026): AdvisorShares had to restate NAV on the 2x leveraged MSOX for Dec 22, 2025 – Feb 2, 2026 because the fund administrator booked swap-income accruals incorrectly. The operational plumbing is fragile.
• Dan Ahrens (AdvisorShares portfolio manager) has publicly said that even if uplisting happens, MSOS will continue using swaps for portions of the portfolio. The synthetic structure isn't going anywhere fast — but it does mean MSOS is the price-discovery vehicle for a sector whose underlying equities barely trade. The tail wags the dog intraday.

There is also a real counterparty-pullout tail risk. If Nomura (22% of the book) walks, MSOS has to unwind into the OTC market that doesn't have the bid. No documented emergency has happened, but the structure is one regulatory letter away from systemic friction.

The broader access universe

If you can't or won't hold MSOs directly, the alternatives all have wrinkles:

• IIPR (NYSE) — cannabis REIT. Trades at 0.74x tangible book, ~14.3% dividend yield as of late 2025, but the dividend currently exceeds cash flow. Committed $270M to IQHQ life-science REIT in 2025 — quiet diversification away from pure-play cannabis. Real estate, not plant.
• NLCP (OTCQX) — triple-net cannabis REIT, ~11-13% yield, 82% payout. Extremely under-leveraged ($433M gross real estate, $7.6M debt). Interesting Q1 2026 data point: Walgreens took over a former Cannabist San Diego dispensary lease.
• Chicago Atlantic BDC (NASDAQ: LIEN) — only publicly traded BDC primarily focused on US cannabis. ~30% discount to NAV, ~14% yield, weighted-avg debt yield 15.8%, zero non-accruals, GAAP leverage 8.2%.
• AFCG / REFI — cannabis lenders/REITs listed on NASDAQ.
• Cannabis ETF survivors (per 24/7 Wall St., April 2026): only MSOS, YOLO, and CNBS remain. POTX closed in 2024. THCX is closing.

The lesson: the entire investable universe outside the OTC MSOs themselves is lending to, leasing to, or synthetically tracking the plant — never owning it directly under a US exchange listing.

---

Part 3 — What Uplisting Actually Requires

The quantitative bars (largely a non-issue)

NASDAQ Capital Market initial listing now requires $15M market value of unrestricted publicly-held shares ($5M offering proceeds minimum), per SEC-approved SR-NASDAQ-2025-068 effective January 16, 2026. NYSE requires $40M publicly-held shares, 400 round-lot shareholders, $4.00 minimum price.

Every major MSO clears these by an order of magnitude. Curaleaf has a ~C$2.4B market cap and $1.3B+ revenue. Trulieve, GTI, Verano all comfortable. PCAOB-audited financials? Already done — they're SEC filers. Sarbanes-Oxley compliance? Mostly done. Corporate governance gaps (audit committee independence, internal-control attestation)? Workable in months, not years.

The quantitative hurdle is essentially zero. Every meaningful obstacle is qualitative.

The discretionary barrier — NASDAQ Rule 5101

The real wall is NASDAQ Rule 5101, which grants the exchange "broad discretionary authority over the initial and continued listing of securities... to prevent fraudulent and manipulative acts and practices... and to protect investors and the public interest." NASDAQ's interpretive position — repeatedly cited by Akerman, Goodwin, Foley Hoag, and others — is that it "cannot initially list or continue the listing of a company whose current or planned activities are in violation of U.S. federal law or the law in a jurisdiction where the company operates."

This is policy under a discretionary rule, not a written cannabis-specific prohibition. NYSE invokes parallel discretion under the Listed Company Manual. Neither exchange has issued formal cannabis-specific written guidance. Neither Adena Friedman (NASDAQ) nor Lynn Martin (NYSE) has made a public statement in 2024-2026 specifying what conditions would let MSOs list.

In December 2025, NASDAQ filed SR-NASDAQ-2025-104, adopting new interpretive material IM-5101-3 that expanded its discretion to deny listings for qualitative manipulation/risk concerns even when quantitative standards are met. That rule was aimed at small-cap China issuers, not cannabis — but it signals exchanges are expanding their discretionary moat, not narrowing it.

Where the line currently is

What NYSE/NASDAQ already accept:

• IIPR (NYSE) — landlord to MSOs
• Scotts Miracle-Gro (NYSE) — sold Hawthorne to Vireo Growth in 2026 to maintain compliance
• GrowGeneration, AFCG, REFI, LIEN (NASDAQ) — cultivation supply, finance
• MindMed, Compass Pathways, Atai (NASDAQ) — psychedelics, as FDA-track pharmaceutical R&D
• J&J (Spravato/esketamine, Schedule III), AbbVie (Marinol/dronabinol, Schedule III) — FDA-approved scheduled drugs
• Canadian LPs: Tilray, Canopy Growth, Cronos, Aurora — Canadian-legal, US presence ancillary or held via deferred-acquisition structures
• Coinbase (April 2021 NASDAQ direct listing) — operated in regulatory ambiguity but compliant on AML/MSB structure

What they reject: commercial cultivation, distribution, and possession of marijuana under US federal law. Even within FDA-track Schedule III, the operative line is "are you operating under a federal framework that legalizes your activity?" J&J markets Spravato under an FDA approval. An MSO selling adult-use cannabis in Colorado is not operating under any federal framework that legalizes the activity, regardless of whether the molecule is Schedule I or III.

This is the precedent gap nobody wants to admit. There is no US exchange precedent for listing a company whose primary business violates US federal law. DraftKings listed after PASPA was struck down in 2018 — federal-illegality removal preceded listing, not the reverse. Coinbase was compliant on its own activity (running a registered MSB); the legal contestation was around the assets it traded. The MSO situation has no clean analogue.

The Canopy USA and Tilray "back doors"

Two NASDAQ-listed Canadian LPs have built option structures to preserve listing while warehousing US exposure:

Canopy USA (the heavyweight structure) — Canopy Growth created a separate Delaware entity holding 100% of Acreage Holdings (completed Dec 9, 2024), 100% of Wana, ~77% of Jetty, and ~20% economic in TerrAscend. Canopy Growth holds an equity-method, non-consolidated interest. The key disclosure: full consolidation occurs "following the date that the NASDAQ Stock Market or The New York Stock Exchange permit the listing of companies that consolidate the financial statements of companies that cultivate, distribute or possess marijuana." The April 2026 partial rescheduling does not trip this trigger — the language requires general permission, not medical-only.

Tilray-MedMen — Tilray bought $165.8M of MedMen convertible notes plus warrants in August 2021. Conversion is "dependent upon U.S. federal legalization of cannabis." Notes maturity extended to 2028. MedMen has since collapsed, materially impairing the option value.

Neither has triggered. NASDAQ has not publicly objected. These structures are the closest thing to "in-place uplisting capacity," and they remain dormant.

---

Part 4 — The SAFE Banking Misconception

This is the section where the most-confident takes on cannabis Twitter are the most-wrong.

What SAFE/SAFER Banking actually does: Creates a federal safe harbor protecting banks, credit unions, insurers, payment processors, and ancillary service providers from federal prosecution, asset forfeiture, and adverse regulatory action when serving state-legal cannabis businesses. It is a Bank Secrecy Act / FinCEN carve-out for the financial services sector. Pure plumbing.

What it does not do:

• Does not legalize cannabis
• Does not reschedule cannabis
• Does not authorize national securities exchanges to list plant-touching issuers
• Does not address DTC eligibility for MSOs
• Does not modify Rule 5101

Pablo Zuanic's August 2025 note states the case bluntly: "The SAFE Banking Act would be a 'small positive' for the industry, in that it does not deschedule cannabis and would not enable multi-state operators (MSO) to uplist to leading U.S. stock exchanges." Every securities-practice law firm surveyed — Akerman, Foley Hoag, Foley & Lardner, Goodwin, McGuireWoods, Ropes & Gray, Hogan Lovells, Saul Ewing — agrees.

The bill that would directly authorize exchange listing is the CLIMB Act (H.R. 7987), reintroduced March 18, 2026 by Reps. Reschenthaler (R-PA) and Carter (D-LA). It "would create a safe harbor for national securities exchanges to list the securities of issuers that are cannabis-related legitimate businesses." Sponsor projections: $47.3B in first-year investment, 600,000 jobs. CLIMB has no momentum.

SAFER Banking's status in the 119th Congress: Has not been reintroduced as of May 2026. Senate Banking is now chaired by Tim Scott (R-SC), a longtime cannabis-banking skeptic; Senate Majority Leader John Thune (R-SD) has historically opposed. The 2023 SAFER Banking Act (S. 2860) passed Senate Banking 14-9 in September 2023, never got a floor vote, died with the 118th Congress. A 2025 Cannabis Business Times analysis flatly stated "federal reform [is] unlikely this Congress."

There's also Section 10 confusion worth flagging: Section 10 of SAFE/SAFER (titled "Requirements for Deposit Account Termination Requests and Orders") restrains federal banking regulators from informally pressuring banks to drop specific customers/industries. It is an anti-Operation-Choke-Point provision. It has nothing to do with securities or listings. Retail conflation is rampant; ignore it.

---

Part 5 — The Schedule III Situation (And Why It's Smaller Than You Think)

Timeline through May 2026:

• Aug 29, 2023 — HHS recommends Schedule III to DEA
• May 21, 2024 — DEA publishes Notice of Proposed Rulemaking
• Aug 29, 2024 — Hearing scheduled; ALJ Mulrooney assigned
• Jan 2025 — Hearing canceled; interlocutory appeal on ex parte communications between DEA leadership and rescheduling opponents
• Feb 11, 2025 — Trump nominates Terrance C. Cole as DEA Administrator
• Jul 23, 2025 — Cole sworn in
• Jul 25, 2025 — Cole publishes top-8 DEA priorities; cannabis rescheduling conspicuously omitted
• Dec 18, 2025 — Trump Executive Order: "Increasing Medical Marijuana and Cannabidiol Research" — directs AG to "expeditiously move marijuana from Schedule I to Schedule III"
• Apr 22-23, 2026 — Acting AG Todd Blanche signs Final Order; published Federal Register Apr 28
• Jun 29, 2026 — Scheduled DEA hearing on broader rescheduling of all marijuana (deadline to participate: May 28, 2026 — 12 days from today)

The April 2026 Final Order is much narrower than the cannabis press treated it. It moves only:

1. FDA-approved drug products containing marijuana
2. Marijuana under qualifying state-issued medical licenses

It leaves on Schedule I:

• All adult-use / recreational marijuana
• Bulk and unlicensed marijuana
• Synthetic THC

For an MSO running medical and adult-use operations in the same state, half the revenue moved to Schedule III and half stayed Schedule I. That is the disqualifying fact for uplisting on rescheduling grounds alone.

What Schedule III actually does:

• Eliminates Section 280E tax burden for qualifying state-licensed medical operators. Verano publicly estimated ~$80M/year. Industry-wide free cash flow swing: hundreds of millions. This is the near-term financial event.
• Does not legalize cannabis federally. Schedule III substances remain controlled.
• Does not preempt state law.
• Does not address banking — FinCEN guidance and BSA obligations are unchanged in legal substance.
• Does not directly address exchange listing.
• Requires plant-touching MSOs to obtain DEA registration to handle Schedule III marijuana — a 60-day expedited filing window with a six-month processing target. Verano filed first. Adult-use operations remain in clear CSA violation regardless.

There is also a DOJ-enforcement coherence problem. The December 2025 EO directs rescheduling. But a reported September 29, 2025 internal DOJ memo from AG Pam Bondi reportedly directs federal prosecutors to enforce simple cannabis-possession crimes; a November 13, 2025 announcement signaled prosecutions will no longer be "significantly curtailed" by Biden-era policies. There is no written Trump-era replacement for the Cole Memo. Exchanges parsing this for listing-comfort signals are seeing mixed messages from inside the same administration.

---

Part 6 — The Disparate Expert Opinions, Mapped

Here's the disagreement landscape that's driving everyone crazy:

Pablo Zuanic (independent equity analyst) — Schedule III is necessary but insufficient. SAFE alone is also insufficient. The path requires broader rescheduling plus a securities-specific safe harbor like CLIMB plus an exchange policy change. Retail accounts for roughly 95% of MSO free float today.

Akerman LLP — Three things have to happen in parallel: (a) broader rescheduling of all marijuana, (b) the CLIMB Act or a similar securities safe harbor, and (c) a "formal policy shift by the exchanges themselves." Adult-use revenue is the disqualifier today.

Foley & Lardner — Partial rescheduling alone is "not ordinarily incompatible with exchange listing" (citing the J&J precedent) — but the dual-license problem and the DEA-registration gap persist for MSOs.

Foley Hoag — Rescheduling "does not immediately resolve the uplisting, banking, and anti-money laundering challenges"; the risks are "at least optically mitigated."

Goodwin, McGuireWoods, Ropes & Gray, Holland & Knight, Saul Ewing — Uniformly cautious. April 2026 delivers 280E relief for medical operations only. No automatic listing pathway opens. The banking landscape is legally unchanged.

Industry CEOs (Boris Jordan, Kim Rivers, Ben Kovler, George Archos, Charlie Bachtell) — Increasingly bullish on 280E relief, but conspicuously avoiding specific uplisting timelines. A marked shift in tone from 2023 confidence.

Dan Ahrens (AdvisorShares, MSOS portfolio manager) — Rescheduling alone is insufficient. The sector also needs DOJ guidance on states' rights and banking/FinCEN reform. The MSOS swap structure persists regardless.

MJBizDaily, Motley Fool, and most retail press — Frame rescheduling as a near-term uplisting catalyst.

ATACH policy paper (drafted by Duane Morris) — Exchanges could move unilaterally under existing federal-enforcement-deference doctrine, but won't without explicit legal cover.

The cleanest summary: legal-practitioner consensus is materially more cautious than equity-analyst and retail-press consensus. When a publication tells you "uplisting is imminent because of rescheduling," check whether the author has read NASDAQ Rule 5101.

---

Part 7 — The Trulieve Delaware Move (And What It Really Signals)

On May 13, 2026 — three days ago — Trulieve announced a proposed Plan of Arrangement to continue out of British Columbia and concurrently domesticate as a Delaware corporation. Key dates: record date June 8, 2026; special shareholder meeting August 5, 2026; proxy filing pending. The Board retains the right to abandon even after shareholder approval.

What it does not say: The press release does not contain a direct Kim Rivers quote and does not mention NYSE/NASDAQ uplisting. The stated rationale is the "favorable corporate environment afforded by Delaware" to "align organizational structure with operations in the United States and help the Company conduct its business more effectively." Governance, alignment, M&A flexibility — not uplisting prep.

That framing is itself the tell. Telegraphing exchange-policy speculation in a press release would invite SEC scrutiny and exchange-staff irritation. The discreet framing lets Trulieve position without speculating.

Does redomicile actually unlock uplisting?

Technically, no. Tilray (BC-incorporated), Canopy Growth (Canada), Cronos, Aurora, Compass Pathways, MindMed all list on NASDAQ as foreign private issuers (FPIs). Domicile is not the bar.

What redomicile actually buys you:

• Signaling — positions the company as a US operating entity ready to be treated as such
• Governance predictability — Delaware corporate law is more M&A-friendly, activist-defense-tested, and litigation-mature than BC corporate law
• M&A flexibility — stock-for-stock deals with US targets are cleaner with a US-corp acquirer; better tax treatment for target shareholders; no Canadian Plan of Arrangement required
• Tax simplification — eliminates Canadian corporate filings, reduces currency/jurisdictional friction
• FPI conversion — once domesticated, the company becomes a US domestic filer with full proxy, Reg FD, 10-K/10-Q regime. This is more burdensome than FPI status, which is itself a tell that the rationale is operational, not cosmetic

Section 7874 (the IRS anti-inversion rule) doesn't apply — that's designed for the opposite direction (US-to-foreign). For Canadian shareholders, the continuance triggers Canadian tax analysis (deemed disposition at the corporate level; shareholders typically roll over basis in a properly-structured share-for-share exchange). The proxy will contain the full tax disclosure.

The redomicile map

Verano — Now domiciled in Nevada, effective Nov 3, 2025. Previously British Columbia. Board approved Sept 15, shareholders voted Oct 27, BC court signed off Oct 30, deal closed Nov 3.

Trulieve — Currently British Columbia, moving to Delaware pending the Aug 5, 2026 shareholder vote. Announced May 13, 2026.

Curaleaf — British Columbia. No redomicile announced; already TSX-listed.

Green Thumb Industries — British Columbia. No redomicile announced.

Cresco Labs — British Columbia. No redomicile announced.

TerrAscend — Ontario. No redomicile announced; already TSX-listed.

Ascend Wellness — Delaware since 2021, pre-IPO. Has always been ready.

The pattern: Verano was first (Nov 2025 Nevada), Trulieve is second (Aug 2026 Delaware), Ascend was always Delaware. GTI, Cresco, and BC-domiciled Curaleaf are conspicuously not on this train. The TSX MSOs (Curaleaf, TerrAscend) appear to be betting their TSX listings + Canadian domicile + restructured US ops will let them move directly to a NYSE/NASDAQ secondary listing without a redomicile detour.

Curaleaf's TSX uplisting — what actually happened

Worth correcting a common misimpression: Curaleaf's TSX uplisting succeeded. Trading on TSX as "CURA" began Dec 14, 2023. CSE delisted Dec 13, 2023. The company conducted a marketed offering Oct 3, 2023 to satisfy a TSX listing condition.

But it has not delivered the institutional buying surge that bulls hoped for. Stock hit C$8.73 in April 2024 (rescheduling rumors), crashed to C$0.99 in June 2025 (rescheduling stall), recovered 83% over the trailing year. Revenue $1.34B in 2024, down 0.28% YoY. The lesson: a Canadian-venue uplisting is not a substitute for a US-venue uplisting for institutional access purposes. The CIBC/BNN research view that TSX uplisting meaningfully expands institutional access has not been validated by Curaleaf's experience.

---

Part 8 — The Comparables, Honestly Assessed

People throw around DraftKings and Coinbase as MSO uplisting precedents. Let's be precise about what each actually shows.

DraftKings (NASDAQ: DKNG, April 24, 2020). Listed via SPAC merger with Diamond Eagle Acquisition + SBTech. Critical context: PASPA was struck down by SCOTUS in Murphy v. NCAA (2018). UIGEA (2006) had already exempted fantasy sports specifically. So the federal-illegality concern had been judicially removed before listing, and individual states were already legalizing sports betting. Federal-illegality removal preceded listing. This is the opposite of the MSO situation, where the federal Controlled Substances Act remains in force.

Flutter (NYSE: FLUT, primary listing transferred May 31, 2024). Already LSE-listed; transferred primary to NYSE after FanDuel scale made US capital markets the natural home. Cleanest "primary listing migration" precedent — but presupposes the underlying business is federally lawful. Migration precedent without illegality issue. Lesson for cannabis: post-uplisting migration mechanics work fast; pre-uplisting legality is the gating event.

Coinbase (NASDAQ: COIN, April 14, 2021). Direct listing despite massive regulatory ambiguity. The trick: Coinbase the exchange wasn't itself the security; they ran a registered Money Services Business, had clean BSA/AML compliance, and the underlying assets (BTC, ETH) weren't deemed securities. Structural compliance and activity-level legality can clear listing even when the broader market is contested. Closest cannabis analogue: an MSO that operates only as a service provider (POS, software, logistics) could potentially clear listing without rescheduling. A cultivator/dispensary cannot.

Psychedelics (MindMed, Compass Pathways, Atai on NASDAQ). Schedule I substances (LSD, psilocybin) — same legal class as marijuana — but listed on NASDAQ. Critical difference: these are FDA-track pharmaceutical R&D companies operating under DEA Schedule I research registrations. Their controlled-substance activity is legal under federal law because it's research. An MSO's controlled-substance activity is not. The lesson: regulatory activity framework matters more than regulatory substance status.

FDA-approved Schedule III drugs (Spravato / J&J, Marinol / AbbVie). Both NYSE-listed without issue. These show the exchanges have no allergy to Schedule III — but the activity is operating under FDA approval, not under state cannabis licenses outside any federal framework.

Net of precedents: No US-domiciled company whose primary business violates US federal law has uplisted to NYSE or NASDAQ. Every analogue had either (a) federal-illegality removal first or (b) FDA-track legalization of the activity. The MSO situation has no clean precedent. Either an MSO becomes the first, or the law changes to match an existing template (CLIMB Act, broader rescheduling, full descheduling).

---

Part 9 — Realistic Timelines

Three scenarios. Probabilities are this author's calibration of the research:

Bear case (~30%)

June 29, 2026 hearing produces a slow ALJ process; broader rescheduling stalls or is litigated. The Mulrooney interlocutory appeal that derailed the 2025 hearing remains procedurally unresolved. CLIMB and SAFER not reintroduced or fail to clear Senate Banking under Scott/Thune. Bondi DOJ continues mixed signals. Exchanges hold the line.

First plant-touching MSO uplisting: post-2028, possibly never under current statutory framework.

Base case (~50%)

June 29, 2026 hearing leads to a Final Order in late 2026 or 2027 placing all marijuana on Schedule III. SAFER or CLIMB advances narrowly in late 119th or 120th Congress. Exchanges revise listing criteria after a combination of broader rescheduling + targeted securities legislation. A single medical-only-pure-play operator goes first (potentially a Verano-style spin-co), followed by full diversified MSOs.

First plant-touching MSO uplisting: late 2027 to mid-2028.

Bull case (~20%)

Trump pushes faster; broader rescheduling Final Order by Q4 2026; DOJ issues an updated non-enforcement memorandum; Treasury issues retrospective 280E guidance; CLIMB-style language attaches to a must-pass vehicle in the 120th Congress; one or both exchanges signals openness. First mover is a medical-only spinco from a major MSO.

First uplisting: late 2026 / early 2027.

Gating events to watch (in order)

1. May 28, 2026 — Deadline to participate in the June 29 DEA hearing on broader rescheduling
2. June 29, 2026 — DEA hearing
3. August 5, 2026 — Trulieve Delaware redomicile shareholder vote
4. Q3-Q4 2026 — Any DEA Final Order on broader rescheduling
5. Q4 2026 — Senate Banking posture under Scott; reintroduction (or not) of SAFER/CLIMB
6. 2026 midterms — Composition of 120th Congress
7. Any major MSO receiving (or being denied) DEA registration
8. Any NASDAQ/NYSE-listed Canadian LP triggering acquisition of a US MSO (Canopy USA, Tilray-MedMen options)
9. Treasury/IRS guidance on 280E retrospective relief

Mechanics, once policy shifts

Realistic timeline from "policy shifts" to "first day of NYSE/NASDAQ trading":

• 4-7 months for the prepared (Trulieve post-redomicile, Verano post-Nevada, Curaleaf, GTI as SEC filers)
• 9-12 months for less-prepared MSOs

Faster than most expect because the SEC reporting / PCAOB audit / Sarbanes-Oxley / governance infrastructure is largely already built. Steps: pre-clear with exchange staff (4-8 weeks), file S-1/F-1 (8-12 weeks to first comment), reverse split if needed, CSE delisting (30-60 days). Russell index inclusion would follow at the next June reconstitution if uplisting clears by April rank day.

---

Part 10 — Post-Uplisting Trading, and Who Loses

Day-one and beyond

The cleanest proxy for an uplisting-quality reaction is the December 18, 2025 Trump EO market response: Tilray +44% intraday, Canopy +52%, Aurora +13%, Cronos +12%. The rally retraced within weeks as the April 2026 DOJ Final Order proved narrower than priced. That suggests roughly the right magnitude for an uplisting catalyst — large intraday moves, partial retracement absent further follow-through.

Historical OTC-to-NASDAQ uplistings have shown sustained 15-30% multiple expansion and 3-5x average daily volume. Borrow costs on MSO OTC shares are currently 50-100%+ annualized; NYSE/NASDAQ uplisting would crush borrow rates and likely see initial short-build followed by squeeze-risk on positive news. Russell inclusion earliest practical date: June 2027 reconstitution if uplisting completes by April 2027 rank day.

Who loses

This is the under-covered piece:

• The CSE. Loses the bulk of its high-profile listings and market-data revenue. Verano's CFO publicly stated: "I do not anticipate that a year from now there are going to be nearly as many, if any, U.S. THC cannabis companies on the CSE."
• OTC Markets Group. Loses the OTCQX cannabis tier — Curaleaf, Trulieve, GTI, Cresco, Verano are currently OTCQX.
• MSOS ETF. Structural relevance erodes, though Ahrens correctly notes swap exposure for non-uplisted names persists.
• Specialized OTC market makers (Cantor, Canaccord, Beacon Securities, etc.). Lose franchise advantage as bulge-bracket banks enter.
• Private credit funds. Curaleaf's recent $500M senior secured at 11.5% — the cannabis-risk premium is still ~600-800 bps over comparable B/B+ industrial. Uplisting + Schedule III opens bank loan markets and crushes that spread.
• Cannabis-focused law and tax practices specializing in CSE/OTC compliance and 280E lose work.
• Cannabis ETFs themselves — once direct ownership is possible at low cost, the swap structure's value proposition collapses.

---

Part 11 — Smart Money Positioning Now

The accumulation pattern is visible even though OTC trading sits outside Section 13(f) reporting requirements (one of the under-discussed implications of the OTC tier — institutional ownership is structurally underreported in MSO names; listed-share status would force disclosure of swap/derivative positions that may already exist).

What's visible:

• Boris Jordan (Curaleaf Exec Chairman) has publicly confirmed "conversations with the Nasdaq about listing." Curaleaf bought out the remaining strategic investor stake in Curaleaf International effective July 2, 2025 — consolidating ownership ahead of any cap-structure event. Public framing post-Dec 18 EO: "biggest legislative change for cannabis in 55 years."
• Jason Wild (TerrAscend Exec Chairman, JW Asset Management) beneficially owns 93.8M TerrAscend shares per the August 2025 13D/A — 29.54% of the company. Steady accumulation through the cycle, not trimming.
• Curaleaf $500M debt placement in early 2025 at 11.5% senior secured, oversubscribed, brought in 10 first-time cannabis lenders. A meaningful expansion of the credit base.
• Trulieve paid off $368M of debt well ahead of its 2026 maturity — de-risking the balance sheet ahead of redomicile.
• Verano is in proactive refinancing on its October 2026 term loan.
• Aggregate sector debt maturing by end of 2026: ~$6B. The winners (Curaleaf, Trulieve, GTI, Verano — all with asset coverage >1.0x) will dominate post-rescheduling. The losers (already visible in Schwazze's restructuring) become consolidation targets.
• Dedicated cannabis funds — Poseidon, Merida ($252M AUM), Tress, Subversive — remain active but capital-constrained. Fund flows still depressed off 2021 peaks.

The structural read: the major MSOs are quietly preparing the operational machinery for an uplisting that's not yet legally available. Trulieve's redomicile, Verano's redomicile, Curaleaf's debt refinancing and TSX listing, the major operators' SEC-filer status and PCAOB audits — these are infrastructure investments that only pay off if uplisting happens. Smart money is paying for option value.

---

Part 12 — What the Disparate Opinions Get Wrong

Five corrections that fall out of this research:

1. "SAFE Banking will enable uplisting." False. SAFE Banking addresses depository institutions, not securities exchanges. The bill that addresses securities exchanges is the CLIMB Act, and it has no momentum. Conflating the two is the most common error in retail cannabis commentary.

2. "Schedule III clears the path to NYSE/NASDAQ." False as currently structured. The April 2026 partial rescheduling covers only FDA-approved drugs and state-licensed medical operations. Adult-use revenue — which drives the majority of every major MSO's top line — remains Schedule I. Even broader rescheduling (June 29 hearing notwithstanding) doesn't override NASDAQ Rule 5101 unless exchanges revise their interpretive policy.

3. "Trulieve's Delaware move is uplisting prep." Half-true. It's positioning and signal, not technical enabler. Tilray is BC-incorporated and on NASDAQ. The real benefits of redomicile are governance, M&A flexibility, and tax — uplisting compatibility is downstream of regulatory change, not of corporate domicile.

4. "Curaleaf's TSX uplisting proved the institutional thesis." False. Stock crashed 89% from peak (Apr 2024) to trough (June 2025). Canadian institutional mandates with US-plant-touching exclusions don't differentiate between Canadian venues.

5. "MSOS provides clean institutional exposure." Half-true. The ETF works mechanically but is held together by total return swaps with five non-US-bank counterparties (Nomura 22%, plus NBC, Marex, CF Secured, Clear Street). One counterparty pullout would force-unwind into illiquid OTC markets. The MSOX restatement of Feb 2026 illustrates the operational fragility. Bulge-bracket US bank participation remains zero.

---

The Bottom Line

The MSO uplisting question reduces to three layered events that must occur, none of which has occurred:

1. Broader rescheduling (all marijuana to Schedule III, not just medical) — gating event is the June 29, 2026 DEA hearing; realistic Final Order late 2026-2027
2. Securities-specific federal cover — CLIMB Act or analogous safe harbor; currently no momentum but not impossible in the 120th Congress
3. Exchange policy revision — NASDAQ Rule 5101 interpretive change or NYSE equivalent; will not move unilaterally without (1) and (2)

The realistic timeline for first plant-touching US-domestic MSO uplisting is late 2027 to mid-2028 in the base case, with bull case late-2026/early-2027 (probably a medical-only spin-co first) and bear case post-2028 or never under current statutory framework.

Smart money is positioning — Verano and Trulieve redomiciles, Curaleaf's credit-base expansion, Jason Wild's 29.5% TerrAscend accumulation, the major operators' SEC-filer infrastructure investments. The cheap option is to own the names that are already prepared to flip the switch the moment regulation moves.

Smart money is also hedging. The MSOS swap counterparty list — five years in, still no bulge-bracket US bank — is the most honest measure of institutional comfort the sector has. It hasn't materially improved. Until JPMorgan or Goldman writes a cannabis swap, the bull case is running on hope.

If you're trying to find the signal in disparate expert opinions: trust the law firms over the equity analysts, trust the equity analysts over the cannabis press, and trust the swap counterparty list over all of them. The plumbing tells the truth.

---

Key sources: NASDAQ Rule 5101 + IM-5101-3 (SR-NASDAQ-2025-104); SEC SR-NASDAQ-2025-068 (effective Jan 16, 2026); NYSE Listed Company Manual §102.01; DEA Final Order Apr 22, 2026 / Federal Register Apr 28, 2026; White House EO Dec 18, 2025; H.R. 7987 (CLIMB Act); S. 2860 (SAFER Banking 118th); Trulieve PR May 13, 2026; Verano PR Nov 4, 2025; Canopy Growth investor disclosures (Canopy USA); Akerman LLP "Rescheduled but Not Listed" Apr 2026; Foley Hoag DOJ Schedule III analysis Apr 2026; Foley & Lardner Schedule III commentary Apr 2026; Zuanic & Associates Aug 2025; AdvisorShares MSOS prospectus and counterparty disclosures; MJBizDaily and New Cannabis Ventures reporting 2024-2026.